Robert Sebra
Papers
2
Total Citations
145
H-Index
2
About
Robert Sebra is a pioneering researcher at the intersection of functional genomics and precision oncology, best known for developing innovative personalized medicine platforms that bridge basic biology and clinical care. His major contributions center on creating living-organism-based drug screening systems to identify effective treatments for patients with rare or treatment-resistant cancers. In his landmark 2019 study (107 citations), Sebra developed a robotics-based personalized platform using Drosophila, which identified the combination of trametinib and zoledronate as an effective therapy for a patient with KRAS-mutant metastatic colorectal cancer. This treatment produced a significant partial response in both target and nontarget lesions, with disease stability lasting 11 months—a remarkable outcome for a challenging case. His 2021 work (38 citations) extended this approach to adenoid cystic carcinoma, a rare salivary gland cancer with limited treatment options, demonstrating the platform's versatility. Sebra’s work exemplifies how functional screening in model organisms can translate into tangible clinical benefits, offering hope for patients with genomically complex or rare malignancies. His achievements highlight the power of interdisciplinary collaboration in advancing precision medicine.
Research Focus
Key Achievements
Top Papers
- 1
- 2